Teicoplanin and vancomycin as treatment for glycopeptide-susceptible Enterococcus faecium bacteraemia: a propensity score-adjusted non-inferior comparative study
Journal of Antimicrobial Chemotherapy · 2023
DOI: 10.1093/jac/dkad079 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2023. Verfasst von Ryo Yamaguchi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The University of Tokyo Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Enterococcus faecium, Acute Kidney Injury, Bacteremia. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Objectives
Limited evidence is available regarding alternative therapeutic agents to vancomycin in treating glycopeptide-susceptible Enterococcus faecium (GSEF) bacteraemia. This study assessed the effectiveness and safety of teicoplanin compared with vancomycin for treating GSEF bacteraemia. Patients and methods This was a retrospective, non-inferiority cohort study. Patients aged ≥18 years who developed GSEF bacteraemia and received either teicoplanin or vancomycin were included. The primary effectiveness outcome was the clinical success at the end of treatment, with a generalized linear model using the propensity score for selecting the agent as a covariate. We used an absolute difference of 20% in clinical success as the non-inferiority margin. Using multivariable logistic regression, the primary safety outcome was the incidence of acute kidney injury (AKI).
Results
In total, 164 patients (74 and 90 in the teicoplanin and vancomycin groups, respectively) were included. Overall, 64.9% (48/74) and 48.9% (44/90) of patients in the teicoplanin and vancomycin groups, respectively, achieved the primary effectiveness outcome. A generalized linear analysis showed an adjusted effectiveness difference of 9.9% (95% CI, −0.9% to 20.0%; P = 0.07), indicating non-inferiority of teicoplanin versus vancomycin. The incidence of AKI was 8.1% (6/74) and 24.4% (22/90) in the teicoplanin and vancomycin groups, respectively, with an adjusted OR of 0.242 (95% CI, 0.068 to 0.864; P = 0.029), indicating significantly lower AKI risk in the teicoplanin than in the vancomycin group.
Conclusions
Teicoplanin is a safe and useful alternative therapeutic agent for treating GSEF bacteraemia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The University of Tokyo Hospital, Tokyo, Japan.
- The Education Center for Clinical Pharmacy, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan.
- Department of Infectious Diseases, The University of Tokyo Hospital, Tokyo, Japan.
- Department of Infection Control and Prevention, The University of Tokyo Hospital, Tokyo, Japan.
ORCID-Profile: Ryo Yamaguchi, Koh Okamoto, Sohei Harada
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Yamaguchi, R., Yamamoto, T., Okamoto, K., Harada, S., Echizenya, M., Tsutsumi, T., & Takada, T. (2023). Teicoplanin and vancomycin as treatment for glycopeptide-susceptible Enterococcus faecium bacteraemia: a propensity score-adjusted non-inferior comparative study. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkad079
Vancouver
Yamaguchi R, Yamamoto T, Okamoto K, Harada S, Echizenya M, Tsutsumi T, et al. Teicoplanin and vancomycin as treatment for glycopeptide-susceptible Enterococcus faecium bacteraemia: a propensity score-adjusted non-inferior comparative study. Journal of Antimicrobial Chemotherapy. 2023. doi:10.1093/jac/dkad079
BibTeX
@article{Yamaguchi2023,
author = {Yamaguchi, Ryo and Yamamoto, Takehito and Okamoto, Koh and Harada, Sohei and Echizenya, Miho and Tsutsumi, Takeya and Takada, Tappei},
title = {Teicoplanin and vancomycin as treatment for glycopeptide-susceptible Enterococcus faecium bacteraemia: a propensity score-adjusted non-inferior comparative study},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2023},
doi = {10.1093/jac/dkad079}
}
EUVIMED